ISSN: 2996-0940
Research Article
Science Set Journal of Ophthalmology and Eye Care

Visual Evoked Potential Findings in the Patients Experiencing Headache as a Consequences of Dinogest Treatment

Fatemeh Aflaki[1], M Seyed Mohammad Masoud Shushtarian[2], Mohammad Eslami Vaghar[3]*, & Ahmad Shojaei[4]

[1]*Department of Biophysics and Biochemistry, Faculty of Advance Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.*
[2]*Department of Biophysics and Biochemistry, Faculty of Advance Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.*
[3]*Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.*
[4]*Basir Eye Health Research Center, Iran University of Medical Sciences, Tehran, Iran.*

***Corresponding author:** Mohammad Eslami Vaghar , Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Submitted:09 June April 2025 **Accepted:** 16 June 2025 **Published:** 23 June 2025

https://doi.org/10.63620/MKSSJOEC.2025.1031

Citation: *Aflaki, F., Shushtarian, S. M. M., Vaghar, M. E., & Shojaei, A. (2025). Visual Evoked Potential Findings in the Patients Experiencing Headache as a Consequences of Dinogest Treatment. Sci Set J of Opthamology & Eye Care, 4(3), 01-04.*

Abstract

Purpose: *The aim of present study was to look for possible visual evoked potential (VEP) changes in the patient's experiencing headache as a consequence of Dinogest treatment.*

Patients and Methods: *A total of 22 eyes from 11 females aged between 25 and 42 years who received Dinogest for the treatment of endometriosis and expriencing headache as a side effect of Dinogest were included as the case group. VEP measurements were taken from the case group and compared with results from 22 eyes of 11 healthy females with no history of Dinogest use, who served as the control group.*

Result: *There were no significant differences between the case and control groups in terms of the latency and amplitude of VEP P100 Peak.*

Conclusion: *No VEP changes was observed in the endometriosis Patients using Dinogest and experiencing headache as a consequence of treatment.*

Keywords: Headache, Dinogest, Endometriosis, Visual Evoked Potential.

Introduction

Endometriosis is defined as the presences of endometrial tissue (glands and stroma) outside the uterus. This disease is often associated with infertility and causes chronic pain in many, but not all, women. In fact, endometriosis affects approximately 10% of women of reproductive age [1]. The treatment of endometriosis should be individualized according to the clinical situation and the suspected level of impairment. Dignogast is an oral derivative of 13- nortestrone that has recently been introduced for the treatment of endometriosis. Like any other drug, Dinogest may have adverse drug reaction (ADRS). The most frequently reported ADRS for Dinogest are abnormal uterine bleeding, increased weight, and headache [2].

The visual system, particularly the visual pathway is an area that has not been extensively studied in this context. Visual evoked potential (VEP) is a suitable technique which has been used for different physiological and pathological conditions of visual system and mainly visual pathway disturbances [3-48]. Therefore, the authors used VEP to assess the visual pathway of patients with endometriosis and suffering from headache as a consequence of Dinagest treatment.

Patients and Methods

In this case-control study, we evaluated 22 eyes from 11 female patients with endometriosis who were undergone Dinogest treatment and expriencing headache as a side effect of Dinogest drug. Infact Dinogest treatment was prescribed by a gynecologist.

These patients comprised the case group. To examine the visual pathway of the case group, visual evoked potential (VEP) testing using pattern stimulation was performed with a Mangoni device. For comparison, 22 eyes from 11 healthy females with an age range similar to that of the case group were included as the control group. The control group underwent the same VEP testing. The latency and amplitude of VEP P100 Peak were measured in milliseconds (msec) and microvolts (μV), respectively to assess the participants visual pathway.

The VEP recordings were conducted using three electrode connected to Mangoni machine. The active electrode was placed on the occipital region, the reference electrode on the vertex and the ground electrode on the forehead.

Results

The average age for the case and control groups was 32.59 ± 5.49 years and 33 ± 5.59 years, respectively (Table 1). There were no statistically significant differences between the two groups in terms of age (p= 0.759); sex (all participants were female), or best-corrected visual acuity (10/10 for all participants).

Table 1: Comparison of average age in case and control groups.

Variable	Number of participants	groups (Mean ± SD)		P value*
Age	11	Control	Case	
		33 ± 5.59	32.59 ± 5.49	0.759
Based on Mann-Whitney U Test				

Table 2 shows the comparison of the latency and amplitude of the VEP, P100 Peak between the case and control groups.
It was observed that there were no statistically significant differences between the two groups in terms of latency (P=0.729) or amplitude (P= 0·827) of the VEP P100 Peak.

Table 2: Comparison of amplitude and latency of VEP P100 in case and control groups.

Variable	Number of participants	groups (Mean ± SD)		P value*
		Control	Case	
Amplitude (μv)	11	6.72 ±1.8	6.81 ±2.44	0.827
Latency (msec)	11	97.9 ±2.86	98.18 ±3.08	0.729
* Based on Mann-Whitney U Test				

Discussion

The present study was planned out to investigate the probable visual pathway changes in the endometriosis patients suffering from headache as a consequences of Dinogest treatment. Visual evoked potential was used for this purpose. The results of the present study showed no significant differences between the healthy and Patient groups in term demographic characteristics such as age, sex, and best corrected visual acuity (BCVA). Moreover, the authors did not observe any Pathological changes in the VEP Patterns between the case and control groups. In fact, there are little literature regarding this specific topic and the most relevant works confined to the two works reported by the authors of present work.

Eslami vaghar M etal 2023 worked on 26 eyes from 13 females who received Dinogest for the treatment of endometriosis. They used VEP test to look for possible side effect of Dinogest in visual pathway and they could not find any pathological changes of VEP in these patients means visual pathway is intact in these Patients, however they taken the total population with or without headache as a Consequences of Dinogest treatment [49] where as we include the patient with headache only.

Another work was reported by shushtarian et al in 2021, which was confined on single Patient with endometriosis and epilepsy who exprienced blurred vision in the left eye. VEP testing showed delayed response in the affected eye, however, the delay was not attributed to Dinogest. The delay was likely due to the patient's epilepsy and the long-term use (over 11 years) of other drugs for epilepsy treatment [50]. The above two references may support the result of Present work.

Conclusion

Visual pathway is intact in the endometriosis patients exprienching headache as a consequence of Dinogest treatment and it can be proved by visual evoked potential examination.

References

1. Shafrir, A. L., Farland, L. V., Shah, D. K., Harris, H. R., Kvaskoff, M., Zondervan, K., & Missmer, S. A. (2018). Risk for and consequences of endometriosis: a critical epidemiologic review. Best Practice & Research Clinical Obstetrics & Gynaecology, 51, 1-15.
2. Cho, B., Roh, J. W., Park, J., Jeong, K., Kim, T. H., Kim, Y. S., Kwon, Y. S., Cho, C. H., Park, S. H., & Kim, S. H. (2020). Safety and effectiveness of Dienogest (Visanne®) for treatment of endometriosis: A large prospective cohort study. Reproductive Sciences, 27(3), 905-915. https://doi.org/10.1007/s43032-019-00094-5
3. Sarzaeim, F., Aflaki, F., Shushtarian, S. M. M., & Shojaei, A. (2024). Screening of Visual Pathway in Patients Suffering from Guillain Barre by Visual Evoked Potential. Sci Set J of Ophthalmology & Eye Care, 3(2), 01-04.
4. Shushtarian, S. M. M., & Fatemian, N. (2021). Large Difference in Latency of Visual Evoked Potential P100 Peak in Case of Pattern and Flash Stimulation in a Multiple Sclerosis Patient. Journal of Ophthalmic and Optometric Sciences, 5(2).

5. Sarzaeim, F., Abdolalizadeh, S., Shushtarian, S. M. M., & Shojaei, A. (2022). Visual Evoked Potential Findings in Patients using Anti-Seizure Medicine. Journal of Ophthalmology and Research, 5(3), 123–126.
6. Shushtarian, S. M. M., & Mazar, R. P. (2021). Far Distance Blurry Vision Following Rhinoplasty. Journal of Ophthalmic and Optometric Sciences, 5(1), 71–74.
7. Shushtarian, S. M. M., & Mazar, R. R. (2022). A rare case of visual decline due to intradiscal ozone therapy in a patient with spinal stenosis. Journal of Ophthalmic and Optometric Sciences, 6(4), 27–29.
8. Shushtarian, S. M. M., Shojaei, A., & Papei, A. (2024). Visual Evoked Potential Findings in a Patient Suffering from Herpes Zoster Ophthalmicus. Sci Set J of Ophthalmology & Eye Care, 3(3), 01–03.
9. Shushtarian, S. M. M., Naghitehrani, K. H., Shojaei, A., & Papei, A. (2023). Psychogenic Non-Epileptic Seizure in a Child Following Electrophysiology Examination of the Eyes. Journal of Ophthalmic and Optometric Sciences, 7(2), 44–46.
10. Shushtarian, S. M. M., & Mazar, R. P. (2023). Self-withdrawal of Levetiracetam in a Patient with Epilepsy Leading to Blindness. Journal of Ophthalmic and Optometric Sciences, 7(1), 28–30.
11. Fatemian, N., Shushtarian, S. M. M., & Adhami-Moghadam, F. (2022). Flash Visual Evoked Potential Recording in Patients with Orbital Fracture. Journal of Ophthalmic and Optometric Sciences, 6(2).
12. Shushtarian, S. M. M., & Eslampoor, N. (2023). Evaluating the Effect of Botulinum Toxin on Visual Pathway Measured by Visual Evoked Potential Using Flash and Pattern Reversal Checkerboard Stimulation Techniques. Journal of Ophthalmic and Optometric Sciences, 7(3).
13. Shushtarian, S. M. M. (2021). Dizziness and Nausea Feeling During Pattern Reversal Checkerboard Visual Evoked Potential Recording in A Multiple Sclerosis Patient. Journal of Ophthalmic and Optometric Sciences, 5(3).
14. Shushtarian, S. M. M., Jazayeri, S. Y., & Vafaei, A. (2023). Visual Evoked Potential Findings in Patients with Dyslexia. Journal of Ophthalmic and Optometric Sciences, 7(1).
15. Shushtarian, S. M. M., Mazar, R. P., & Shojaei, A. (2022). Bilateral Vision Loss in a Patient Following Cardiac Surgery. Journal of Ophthalmic and Optometric Sciences, 6(2).
16. Shushtarian, S. M. M., & Mazar, R. P. (2022). Unilateral Blindness in a Patient Following Root Canal Treatment. Journal of Ophthalmic and Optometric Sciences, 6(1).
17. Ameli, S., Panahi Sharif, A., Saleh, S., Shushtarian, S. M. M., & Shojaei, A. (2023). Flash Visual Evoked Potential Recording in Patients with Brain Stroke. Journal of Ophthalmology and Research, 6, 40–44.
18. Shushtarian, S. M. M., Shojaei, A., & Tajik, F. (2018). Visual Pathway Disturbances in Rosai-Dorfman Disease: A Case Report. Journal of Ophthalmic and Optometric Sciences, 2(4), 24–26.
19. Shushtarian, S. M., & Yahyavi, S. H. (1999). Study of visual evoked potentials during normal monthly cycle in normal female subjects. Biomedical Sciences Instrumentation, 35, 165–167.
20. Shushtarian, S. M., Adhami-Moghadam, F., Naser, M., Khazaii, R., Sobhani, S., Shabani, S., & Vojoodi, S. (2017). Electroretinographic Changes in Multiple Sclerosis Patients with Abnormal Visual Evoked Potentials. Journal of Ophthalmic and Optometric Sciences, 1.
21. Naser, M., & Shushtarian, S. M. M. (2020). Need for Visual Pathway Examination of the Patient Prior to Bone Marrow Transplantation. Journal of Ophthalmology and Research, 3(4), 75–78.
22. Shushtarian, S. M., Kalantari, A. S., Tajik, F., & Adhami-Moghadam, F. (2017). Effect of occupational vibration on visual pathway measured by visual evoked potentials. Journal of Ophthalmic and Optometric Sciences, 1(5), 7–11.
23. Keramti, S., Ojani, F., Shushtarian, S. M. M., Shojaei, A., & Mohammad-Rabei, H. (2021). Early Diagnosis of Pathological Changes in Visual System of Prolactinoma Patients Using Visual Evoked Potential. Journal of Ophthalmology and Research, 4(3), 289–293.
24. Ojani, F., Shushtarian, S. M. M., Shojaei, A., & Naghib, J. (2021). Visual Evoked Potential Findings of Bardet-Biedl Syndrome. Journal of Ophthalmology and Research, 4(3), 254–257.
25. Sarzaeim, F., Hashemzehi, M., Shushtarian, S. M. M., Shojaei, A., & Naghib, J. (2022). Flash Visual Evoked Potential as a Suitable Technique to Evaluate the Extent of Injury to Visual Pathway Following Head Trauma. Journal of Ophthalmology and Research, 5, 20–23.
26. Sarzaeim, F., Hashemzehi, M., Shushtarian, S. M. M., & Shojaei, A. (2022). Visual Evoked Potential Findings in Road Drilling Machine laborers. Journal of Ophthalmology and Research, 5(1), 43–47.
27. Allahdady, F., Aghazadeh Amiri, M., Shushtarian, M., Tabatabaee, S. M., Sahraei, F., Shojaei Baghini, A., & Sheibani, K. (2016). Comparison of visual evoked potential and electro-oculogram tests in early detection of hydroxychloroquine retinal toxicity. Journal of Ophthalmic and Optometric Sciences, 1(1).
28. Shushtarian, S. M. M., Shojaei, A., & Adhami-Moghadam, F. (2018). Visual Evoked Potentials Changes among Patients with Chronic Mustard Gas Exposure. Journal of Ophthalmic and Optometric Sciences, 2(2018), 6–9.
29. Shushtarian, S. M. M., Adhami-Moghadam, F., Naser, M., & Shojaei, A. (2017). Severe Headache Initiated by Flash Stimulation during Visual Evoked Potential Recording in a Patient with Monocular Optic Neuritis and History of Migraine Headache. Journal of Ophthalmic and Optometric Sciences, 1(4).
30. Shushtarian, S. M. (2009). Role of Myelin in Synchronization and Rhythmicity of Visual Impulses. In 4th European Conference of the International Federation for Medical and Biological Engineering (pp. 160–162). Springer, Berlin, Heidelberg.
31. 31Shushtarian, S. M. M. (2020). Suitable Stimulation Technique to Record Visual Evoked Potential in Migraine Patients. Journal of Ophthalmic and Optometric Sciences, 4(2), 41–45.
32. Hajibeygi, R., Shushtarian, S. M. M., & Abolghasemi, S. (n.d.). Visual Evoked Potential Findings of Sjogren's Syndrome. Journal of Ophthalmic and Optometric Sciences, 4(1), 13–17.
33. Shushtarian, S. M. M., Tajik, F., & Abdolhoseinpour, H. (2018). Measurement of Visual Evoked Potentials in Patients with Spastic Cerebral Palsy. J. Ophthalmic Optom. Sci, 2, 10–13.

34. Shushtarian, S. M. M., Adhami-Moghadam, F., Adhami-Moghadam, P., & Abdolhoseinpour, H. (2018). Electrophysiological Eye Examination Changes in a Patient with Sjogren's Syndrome. Journal of Ophthalmic and Optometric Sciences, 2(1), 40–43.
35. Shushtarian, S. M. M., Mazar, R. P., & Fadaeifard, S. (2021). Visual Evoked Potential Recording in a Fatigued and Drowsy Patient under Anti-Seizure Medicine Treatment. Journal of Ophthalmic and Optometric Sciences, 5(1).
36. Shushtarian, S. M. M., & Dastjerdi, M. V. (2020). Total Blindness Following Anaphylactic Shock due to Co-Amoxiclav Treatment. Journal of Ophthalmic and Optometric Sciences, 4(4).
37. Shushtarian, S. M. M. (2020). Flash and Pattern Reversal Checkerboard Visual Evoked Potential Recording in Albinism Patients. Journal of Ophthalmic and Optometric Sciences, 4(3), 42–46.
38. Fatemian, N., Adhami-Moghadam, F., & Shushtarian, S. M. M. (2021). Study of Visual Evoked Potentials in Patients Suffering from Exotropia. Journal of Ophthalmic and Optometric Sciences, 5(2).
39. Shushtarian, S. M. M., Naghitehrani, K. H., & Aflaki, F. (2020). Diplopia and Flashes of Light Sensation in a Patient with Fragrance Allergy. Journal of Ophthalmic and Optometric Sciences, 4(3).
40. Naser, M., Shushtarian, S. M. M., Shojaei, A., & Adlami-Moghadam, F. (2017). Visual Disturbance in a Patient with Amiodarone Treatment Following Refractive Surgery. Journal of Ophthalmic and Optometric Sciences, 1(3).
41. Shushtarian, S. M. M., Naghib, S. J., Adhami-Moghadam, F., & Shojaei, A. (2020). Diplopia and Blurry Vision Following Refractive Eye Surgery: A Comorbidity Case Report. Journal of Ophthalmic and Optometric Sciences, 4(1), 40–42.
42. Shushtarian, S. M. M., Vaghar, M. E., & Mazar, R. P. (2024). Central Retinal Vein Occlusion Caused by Antipsychotic Drugs: A Case Report. Journal of Ophthalmic and Optometric Sciences, 8(2), 41–43.
43. Shushtarian, S. M. M., Vaghar, M. E., & Mazar, R. P. (2024). Acute Mental Stress as a Precipitating Factor for Central Retinal Vein Occlusion in an Elderly Patient. Journal of Ophthalmic and Optometric Sciences, 8(2), 44–46.
44. Shushtarian, S. M. M., Vaghar, M. E., & Touchahi, K. R. (2024). Total Monocular Blindness Following Blepharoplasty. Journal of Ophthalmic and Optometric Sciences, 8(1), 45–47.
45. Shushtarian, S. M. M. (2024). Psychogenic Vomiting in a Child during Visual Evoked Potential Recording: A Case Report. Journal of Ophthalmic and Optometric Sciences, 6(3), 33–36.
46. Shushtarian, S. M. M., & Shojaei, A. (2023). Visual Evoked Potential Findings in an Eight-Year-Old Girl with Triple-A Syndrome. Journal of Ophthalmic and Optometric Sciences, 7(4).
47. Shushtarian, S. M. M., Abadi, F. M. S., & Adhami-Moghadam, F. (2023). Electrophysiological Eye Examination of a Patient Suffering from Tuberous Sclerosis and Probable Retinal Dystrophy. Journal of Ophthalmic and Optometric Sciences, 7(3), 39–41.
48. Shushtarian, S. M. M., & Mazar, R. P. (2023). Visual Loss Following Cranial Radiotherapy to Treat a Pituitary Tumor. Journal of Ophthalmic and Optometric Sciences, 7(2), 41–43.
49. Vaghar, M. E., & Shushtarian, S. M. M. (2023). Visual Evoked Potential Findings in Endometriosis Patients Treated with Dienogest. Journal of Ophthalmic and Optometric Sciences, 7(4).
50. Shushtarian, S. M. M., Dermani, F. S., & Mazar, R. P. (2021). Blurred Vision in a Patient Suffering from Endometriosis and Epilepsy. Journal of Ophthalmic and Optometric Sciences, 5(4).